HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dietary Ingredient Advisory List Yet To Fulfill Potential For US FDA

Executive Summary

"We haven't utilized the ingredient advisory list quite as much as I'd like to see. But it's something we'll be working on this year,” says Cara Welch, acting director of FDA’s Office of Dietary Supplement Programs.

You may also be interested in...

US Firm Removed From Warnings About Botanicals ‘Removed’ From Lawful Use In Supplements

FDA retracts warning against Glanbia Performance Nutrition Manufacturing about selling adulterated dietary supplements.

US FDA Warns About Botanicals Determined As Unlawful Being Used As Dietary Ingredients

One or more of 5-alpha-hydroxy laxogenin, higenamine, hordenine and octopamine is used by 11 firms FDA warned in products labeled as supplements and marketed as beneficial for weight loss and strength training.

Welch Leads US FDA’s Dietary Supplement Office

Center for Food Safety and Applied Nutrition says Cara Welch selected to fill Office of Dietary Supplement Programs director post. She’ll move up from ODSP deputy director on 14 March.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts